Venturi Wealth Management LLC Purchases New Holdings in 10x Genomics $TXG

Venturi Wealth Management LLC purchased a new stake in shares of 10x Genomics (NASDAQ:TXG) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 17,959 shares of the company’s stock, valued at approximately $208,000.

Other large investors have also recently bought and sold shares of the company. GAMMA Investing LLC boosted its position in 10x Genomics by 81.8% during the first quarter. GAMMA Investing LLC now owns 3,586 shares of the company’s stock valued at $31,000 after purchasing an additional 1,614 shares during the last quarter. Signaturefd LLC boosted its position in 10x Genomics by 134.3% during the first quarter. Signaturefd LLC now owns 4,203 shares of the company’s stock valued at $37,000 after purchasing an additional 2,409 shares during the last quarter. Whittier Trust Co. acquired a new position in 10x Genomics during the first quarter valued at approximately $41,000. PNC Financial Services Group Inc. boosted its position in 10x Genomics by 153.6% during the first quarter. PNC Financial Services Group Inc. now owns 5,150 shares of the company’s stock valued at $45,000 after purchasing an additional 3,119 shares during the last quarter. Finally, US Bancorp DE boosted its position in 10x Genomics by 314.5% during the first quarter. US Bancorp DE now owns 5,973 shares of the company’s stock valued at $52,000 after purchasing an additional 4,532 shares during the last quarter. 84.68% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other 10x Genomics news, insider Benjamin J. Hindson sold 7,486 shares of the firm’s stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total transaction of $103,231.94. Following the transaction, the insider owned 440,888 shares in the company, valued at $6,079,845.52. This trade represents a 1.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Adam Taich sold 22,315 shares of the firm’s stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total value of $307,723.85. Following the transaction, the chief financial officer owned 309,273 shares in the company, valued at approximately $4,264,874.67. This trade represents a 6.73% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 39,149 shares of company stock worth $539,865 in the last 90 days. Company insiders own 9.39% of the company’s stock.

10x Genomics Trading Down 2.0%

Shares of NASDAQ TXG opened at $11.47 on Friday. The firm has a market cap of $1.43 billion, a P/E ratio of -16.39 and a beta of 2.05. 10x Genomics has a 1-year low of $6.78 and a 1-year high of $18.21. The business’s 50 day moving average is $12.98 and its 200-day moving average is $11.06.

10x Genomics (NASDAQ:TXG) last announced its earnings results on Thursday, August 7th. The company reported $0.28 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.63. The company had revenue of $172.91 million for the quarter, compared to analyst estimates of $139.36 million. 10x Genomics had a negative return on equity of 12.88% and a negative net margin of 13.13%.The firm’s quarterly revenue was up 12.9% compared to the same quarter last year. During the same quarter last year, the company earned ($0.32) earnings per share. 10x Genomics has set its Q3 2025 guidance at EPS. Analysts forecast that 10x Genomics will post -1.43 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on TXG. Barclays reaffirmed an “overweight” rating and issued a $15.00 price objective (up from $13.00) on shares of 10x Genomics in a research report on Friday, August 8th. Morgan Stanley cut their price objective on 10x Genomics from $18.00 to $17.00 and set an “overweight” rating for the company in a research report on Tuesday, August 12th. Zacks Research raised 10x Genomics from a “hold” rating to a “strong-buy” rating in a research report on Thursday. Bank of America raised their price objective on 10x Genomics from $12.00 to $13.00 and gave the company a “neutral” rating in a research report on Thursday, June 26th. Finally, Deutsche Bank Aktiengesellschaft set a $14.00 price objective on 10x Genomics and gave the company a “hold” rating in a research report on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, 10x Genomics presently has an average rating of “Hold” and an average price target of $13.65.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.